Patents Examined by Stacey N MacFarlane
  • Patent number: 11564949
    Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: January 31, 2023
    Assignee: The Regents of the University of California
    Inventors: Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla
  • Patent number: 11531030
    Abstract: Complexes containing a labeled polypeptide and an antibody, and the use of such complexes as research, diagnostic, and clinical tools, are described herein.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: December 20, 2022
    Inventors: Wendy K. Nevala, Svetomir N. Markovic, John T. Butterfield, Daniel J. Knauer
  • Patent number: 11506666
    Abstract: A reliable assay to specifically detect CD155 in tissue sections has widespread use because CD155 is expressed widely among tumor types. Additionally, detected expression of CD 155 in glioblastoma cells is at levels commensurate with susceptibility to PVSRIPO (a poliovirus construct) infection and killing. An anti-CD155 antibody can achieve mono-specific detection of CD155 in immunoblots of tumor homogenates and immunohistochemistry of tumor formalin fixed, paraffin embedded sections. The assay can be used to determine appropriate use of PVSRIPO in oncolytic immunotherapy against cancers.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 22, 2022
    Assignee: Duke University
    Inventors: Darell D. Bigner, Vidyalakshmi Chandramohan, Matthias Gromeier
  • Patent number: 11492393
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: November 8, 2022
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 11478556
    Abstract: In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: October 25, 2022
    Assignee: The Regents of the University of California
    Inventors: Yury Miller, Tony L. Yaksh
  • Patent number: 11413325
    Abstract: Disclosed are compositions and methods for promoting survival of or axon regeneration in neurons by increasing mitochondrial motility in the neuron. Also disclosed are methods to treat neuronal injury and disease and disorders characterized by neuronal injury. Agents that increase Armcx1 activity, such as Armcx1 polypeptide or vectors comprising nucleic acid encoding Armcx1 polypeptide, are proposed for use in the methods. Pharmaceutical composition comprising the agents, and methods for identifying additional agents are also disclosed.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 16, 2022
    Inventors: Zhigang He, Thomas L. Schwarz, Cartoni Romain
  • Patent number: 11357758
    Abstract: Provided are epithelial cell spheroids including spheroids that have apical membranes and cilia that face towards the interior core of the spheroid and spheroids that have apical membranes and cilia that face away from the interior core of the spheroid. Also provided methods of making and using such spheroids.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: June 14, 2022
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Martina Gentzsch, Scott Randell, Nancy L. Quinney, Susan Boyles, Jennifer Guimbellot
  • Patent number: 11357840
    Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: June 14, 2022
    Assignee: HYPERSTEM SA
    Inventors: Angelo Luigi Vescovi, Elena Binda
  • Patent number: 11359243
    Abstract: The present invention relates to a method for the early diagnosis and prognosis of an inflammatory state of the brain, caused by neurological, neurodegenerative, and/or aging diseases. Said method is based on the qualitative- quantitative evaluation of microglia microvesicles in a subject's plasma.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 14, 2022
    Assignee: BRAINDTECH S.P.A.
    Inventors: Armando Chierchia, Fabio Bianco
  • Patent number: 11352415
    Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 7, 2022
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Thomas E. Prod'Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
  • Patent number: 11346848
    Abstract: The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention relates to a screening assay to produce compounds stabilizing the gamma-secretase enzyme substrate complex, thereby increasing gamma-secretase processivity while attenuating the release of longer A? peptides. More specifically, gamma-secretase stabilizing compounds increase thermostability of the enzyme/substrate complexes acting in the sequential ?-secretase processing of APP, to result in reduced amyloidogenic A? production, thereby preventing Alzheimer disease.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 31, 2022
    Assignees: VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&D
    Inventors: Bart De Strooper, Lucia Chávez Gutiérrez, Maria Szaruga
  • Patent number: 11332513
    Abstract: The present invention is directed to a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv binds to a tumor antigen, (ii) a transmembrane domain, (iii) a co-stimulatory domain of GITR intracellular domain, and (iv) an activating domain. In one embodiment, the tumor antigen is human epidermal growth factor receptor (EGFR), human mesothelin, or human CD19. CARs having GITR intracellular domain as a co-stimulatory domain have certain advantages over other traditional CAR co-stimulatory domains.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: May 17, 2022
    Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., Ltd, The General Hospital Corporation
    Inventors: Lijun Wu, Marcela V. Maus, Vita Golubovskaya
  • Patent number: 11327080
    Abstract: A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain. An agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain is suitable for use in preventing, alleviating or treating traumatic brain injury. A method for predication of the risk of an individual for complications after a traumatic brain injury comprises detecting one or more aggregated forms of one or more peptides prone to aggregate as a result of a traumatic brain injury event, in the brain of the individual, wherein an increased level of such aggregates in the brain indicates an increased risk for complications.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 10, 2022
    Assignee: BioArctic Neruoscience AB
    Inventors: Lars Lannfelt, Hans Basun, Erik Rollman Waara
  • Patent number: 11324798
    Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: May 10, 2022
    Inventors: Theodore E. Maione, Constantine Basil Maglaris
  • Patent number: 11326182
    Abstract: The invention provides compositions and methods for the preparation, manufacture and therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral genomes encoding one or more antibodies or antibody fragments or antibody like polypeptides, for the prevention and/or treatment of diseases and/or disorders.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 10, 2022
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Steven Paul, Donna T. Ward
  • Patent number: 11319527
    Abstract: Methods for expanding proliferating populations of neuronal subtype-specific progenitors and creating substantially pure populations of motor neurons are provided herein. In particular, the present invention provides methods for maintaining the unique gene profile and differentiation potential of neuronal subtype-specific progenitors, such as motor neuron progenitors and hindbrain serotonergic neural progenitors.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 3, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Zhongwei Du
  • Patent number: 11313867
    Abstract: Methods are disclosed for determining whether a subject has a synucleinopathy. Methods are also disclosed for detecting misfolded alpha synuclein (?Syn) in a biological sample or fraction thereof. These methods include the use of an ?Syn seeding assay.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 26, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Byron Winslow Caughey, Bradley Richard Groveman, Christina Doriana Groveman, Lynne DePuma Raymond, Andrew Gregory Hughson
  • Patent number: 11312775
    Abstract: Methods of treating, preventing, inhibiting, delaying the onset of, or ameliorating a neurological immunity disorder can include administering an effective amount of a compound comprising an antibody or antigen binding fragment of an antibody to a subject in need of treatment, prevention, inhibition, delay of onset, or amelioration of a neurological immunity disorder. The antibody or the antigen binding fragment of an antibody binds specifically to CD49a.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 26, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Jonathan Kipnis, Antoine Louveau
  • Patent number: 11298409
    Abstract: The present invention relates to methods of inhibiting neurodegeneration in a subject suffering from or genetically at risk and/or destined to develop Huntington's Disease comprising increasing, in neurons of the subject, the activity of the TIM23 mitochondrial protein import complex.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: April 12, 2022
    Inventors: Robert Friedlander, Hiroko Yano
  • Patent number: 11286297
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: March 29, 2022
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd